|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Participation of K+ chan- nels in the endothelium-dependent and endothelium independent components of the relaxant effects of rosuvastatin in rat aortic rings 显示文摘 | Lopez J Mendoza R Villanueva GC | 2008 | J Cardiovasc Pharmacol Ther2008，13，3： | 1 |
| 2 | The global burden of disease,1990-2020显示文摘 | Lopez AD Murray GC | 1998 | Nat Med1998，4，13： | 1 |
| 3 | Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity 显示文摘 | Ness GC Chambers CM Lopez D | 1998 | J Lipid Res1998，39，1： | 1 |
| 4 | Cytogenetic study of angiosarcoma of the breast显示文摘 | Gil BR Lopez GC Soriano P | 1994 | Genes Chromosomes Cancer1994，10，3： | 1 |
| 5 | Cytogenetic study of angiosarco- ma of the breast显示文摘 | Gil BR Lopez GC Soriano P | 1994 | Genes Chromosomes Cancer1994，10，3： | 1 |
| 6 | Cytogenetic study of angiosarcoma of the breast显示文摘 | Gil BR Lopez GC Soriano P | 1994 | Genes Chromosomes Cancer1994，10，3： | 1 |
| 7 | Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma显示文摘 | Duenas GA Lopez GC Gonzalez A | 2003 | Am J Clin Oncol2003，26，1： | 1 |
| 8 | A phase II study of multimodality treatment for locally advanced cervical cancer:neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation显示文摘 | Duenas GA Lopez GC Gonzalez EA | 2003 | Ann Oncol2003，14，8： | 1 |
| 9 | Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity 显示文摘 | Ness GC Chambers CM Lopez D | 1998 | J Lipid Res1998，39，1： | 1 |
| 10 | Characterization of genetic variation and 3′-azido-3′-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method显示文摘 | Lopez GC Rojas JM Najera R | 1991 | Proc Natl Acad Sci USA1991，88，： | 1 |
| 11 | A phase Ⅱ study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and pachtaxel and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation 显示文摘 | Duenas GA Lopez GC Gonzalez EA | 2003 | Ann Oncol2003，14，8： | 1 |
| 12 | Prospective application of a bleeding and ischemic risks-adjusted antithrombotic protocol in elderly patients revascularized with everolimus-eluting stents:EPIC05-Sierra75 study显示文摘OBJECTIVES Elderly patients show a higher incidence of ischemic and bleeding events after percutaneous transluminal coron-ary intervention(PCI).We sought to investigate outcomes in elderly patients treated with antithrombotic strategy guided by bleeding and ischemic risks after revascularization with last generation everolimus-eluting stent(EES).METHODS Prospective multicenter registry including patients over 75 years revascularized with EES and antithrombotic ther-apy guided by clinical presentation,PCI complexity and PRECISE DAPT score.Co-primary safety endpoints were:(1)composite of cardiac death,myocardial infarction and stent thrombosis and;(2)bleeding(BARC 2-5).Primary efficacy endpoint was target lesion revascularization.A matched group of patients revascularized with current drug-eluting stents and no such tailored antith-rombotic therapy was used as control.RESULTS Finally,1064 patients were included in SIERRA-75 cohort,80.8±4.2 years,36.6%women,71%acute coronary syn-dromes(ACS)and 53.6%complex PCI.Co-primary safety endpoint of major adverse cardiovascular events was met in 6.2%,co-primary safety endpoint of bleeding in 7.8%and primary efficacy endpoint of TKLR in 1.5%.The multivariable adjusted model showed no significant association of the prescribed short/long dual antiplatelet therapy(DAPT)durations with any endpoint suggesting a well tailored therapy.No stent thrombosis reported in the subgroup with 1-3 months DAPT duration.As compared to control group,bleeding BARC 2-5 was significantly lower in SIERRA-75 group(7.4%vs.10.2%,P=0.04)as well as the net safety-efficacy endpoint(14.3%vs.18.5%,P=0.02).CONCLUSIONS In elderly population,the application of this risks-adjusted antithrombotic protocol after revascularization with last generation EES seems to be associated with an improved prognosis in terms of ischemic and bleeding outcomes. | Jose M de la Torre Hernandez Ramon Lopez Palop Jesus M Jimenez Mazuecos Pilar Carrillo Sáez Alejandro Gutierez-Barrios Eduardo Pinar Belen Cid Luis Fernandez Tamara Garcia Camarero Cristóbal Urbano-Carrillo Juan F Oteo Dominguez Victor A Jimenez Diaz Antonio EGomez Menchero Eladio Galindo Fernández Juan GCórdoba Soriano Raymundo Ocaranza Eduardo ArroyoÚcar Koldobika Garcia San Roman Silvio Leal Ginés Martínez Cáceres Jose A Linares Vicente Georgina Fuertes Ferre Xavier Carrillo Juan CRama Merchán Catia Costa Juan Sanchis Renato Fernandes Alberto Rodrigues Jose M Vegas Valle Hélder Pereira Armando Perez de Prado | 2022 | Journal of Geriatric Cardiology2022，19，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员